NCT01095484 - Named Patient Program With Rotigotine Transdermal System | Biotech Hunter

Enrollment

520

Participants

Timeline

Start Date

November 30, 2008

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2012

Conditions

Conditions for Which There is a Documented Medical Necessity to Receive Treatment With Rotigotine

Interventions

DRUG

Rotigotine patch

1 patch daily for up to 48 months. Patch strength (per 24 hours): 1 mg - 8 mg based on investigator's assessment

Trial Locations (51)

Unknown

088, Birmingham

082, Cullman

085, Fairhope

014, Huntsville

097, Gilbert

003, Phoenix

044, Phoenix

036, Berkeley

024, Fountain Valley

034, Irvine

019, Los Angeles

040, Orange

076, Sunnyvale

035, Fort Collins

027, Washington D.C.

070, Atlantis

002, Boca Raton

031, Clearwater

028, Largo

075, Ormond Beach

022, St. Petersburg

004, Tampa

054, Weston

030, Atlanta

041, Honolulu

011, Peoria

025, Destrehan

091, Clinton Township

001, Southfield

042, Warren

037, Ocean Springs

016, West Plains

026, Lincoln

086, Freehold

062, Ridgewood

018, Albany

066, Brooklyn

006, Patchogue

052, Charlotte

093, Salisbury

065, Albany

009, Salem

048, Austin

072, Austin

071, Dallas

046, Houston

005, Kirkland

017, Olympia

012, Spokane

053, Tacoma

056, Milwaukee